Subconjunctival bevacizumab for corneal neovascularization |
| |
Authors: | Mesut Erdurmus Yuksel Totan |
| |
Affiliation: | (1) Department of Ophthalmology, Fatih University Medical School, Alparslan Turkes Cad No: 57, 06510 Emek, Ankara, Turkey |
| |
Abstract: | Objective To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV). Methods This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography. Results Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months. Conclusion Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV. |
| |
Keywords: | Bevacizumab Corneal neovascularization |
本文献已被 SpringerLink 等数据库收录! |